Unlike many antioxidants that come only from food, glutathione is produced within your cells
Dermatol Surg 2010
Manufacturing Complexity Semaglutide is a GLP-1 receptor agonist that requires sophisticated biotechnology manufacturing processes

Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up
:max_bytes(150000):strip_icc()/VWH-GettyImages-2165235773-1856e8f7a2dd403a820cfecb4db69acb.jpg)
Niacinamide serves as a stabilizer for the tirzepatide peptide in solution and provides its own metabolic benefits, including support for NAD+ production and cellular energy metabolism
February 27, 2026: During his appearance on the Joe Rogan Experience (Episode 2461), HHS Secretary Kennedy announced that approximately 14 of the 19 restricted peptides would be moved back to Category 1, restoring a legal pathway for licensed compounding pharmacies